Imiquimod: Immune Response Modifier

Overview / Definition Imiquimod is a topical medication classified as an immune response modifier. It is primarily utilized in dermatology for the treatment of certain skin lesions, including superficial basal cell carcinoma, actinic keratosis, and external genital warts. Imiquimod acts by stimulating the local immune response, leading to the destruction of abnormal cells and promoting healing. Epidemiology Imiquimod is commonly prescribed for: Superficial basal cell carcinoma (BCC) - more prevalent in fair-skinned individuals and those with prolonged sun exposure. Actinic keratosis (AK) - frequently seen in older adults and those with significant UV exposure. Genital warts - associated with sexually transmitted human papillomavirus (HPV) infections, affecting sexually active individuals. Pathophysiology / Mechanism Imiquimod functions by activating the toll-like receptor 7 (TLR7) present on immune cells, particularly dendritic cells and macrophages. This activation triggers the release of pro-inflammatory cytokines such as: Interferon-alpha Interleukin-1 Interleukin-6 Interleukin-12 These cytokines enhance the local immune response, promoting apoptosis of abnormal cells and reducing viral replication in the case of HPV-related lesions. Clinical Presentation Imiquimod is indicated for various skin conditions, each with distinct clinical features: Superficial Basal Cell Carcinoma: Presents as a pearly, dome-shaped papule or plaque, often with telangiectasia. Actinic Keratosis: Appears as rough, scaly patches on sun-exposed areas, often erythematous and sometimes tender. Genital Warts: Characterized by soft, fleshy growths in the genital or anal region, often causing discomfort or itching. Diagnosis / Workup The diagnosis of conditions treated with imiquimod is primarily clinical, supported by: Physical examination of skin lesions. Dermatoscopic evaluation for basal cell carcinoma and actinic keratosis. Biopsy may be performed to confirm diagnosis, especially in ambig